



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 9/16</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 92/01443</b>  <b>(43) International Publication Date:</b> 6 February 1992 (06.02.92)
<b>(21) International Application Number:</b> PCT/GB91/01140 <b>(22) International Filing Date:</b> 10 July 1991 (10.07.91)  <b>(30) Priority data:</b> 9015822.1                      18 July 1990 (18.07.90)                      GB  <b>(71) Applicant (for all designated States except US):</b> BEECHAM GROUP PLC [GB/GB]; SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only) :</b> ATWAL, Upinder, Singh [IN/GB]; SmithKline Beecham Products, St. George's Avenue, Weybridge, Surrey KT13 0DE (GB).		<b>(74) Agent:</b> WHITE, Susan, Mary; SmithKline Beecham, Corporate Patents, Great Burgh, Yew Tree Bottom Road, Epsom, Surrey KT18 5XQ (GB).  <b>(81) Designated States:</b> AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.  <b>Published</b> <i>With international search report.          Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> COMPOSITIONS CONTAINING MICROPARTICLE MATRICES  <b>(57) Abstract</b>  A sustained release drug-polymer microparticle matrix comprising an active drug having basic properties and a blend of pharmaceutically acceptable polymers or copolymers.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU <sup>+</sup>	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

<sup>+</sup> It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

-1-

## COMPOSITIONS CONTAINING MICROPARTICLE MATRICES

This invention relates to drug-containing polymer matrix systems, in particular to such systems offering controlled, sustained and preferably pH-independent drug release, their preparation, pharmaceutical compositions containing them, and their use in therapy.

Microencapsulation is a coating technology well known for use with orally administrable drug materials. The incorporation of drug materials into a drug-polymer matrix by the general process known as solvent evaporation is also known. Matrices formed by solvent evaporation processes have the active substance dispersed throughout the matrix structure. They are thus distinguished from drug microcapsules which have a distinct polymer outer wall.

Matrix structures formed by a solvent evaporation process which gives rise to discrete drug-polymer particles may be either homogeneous, microporous systems or heterogeneous, macroporous systems. Matrix particles are termed homogeneous when the drug is distributed uniformly throughout the polymer structure such that the particles have a translucent appearance. Macroporous matrix particles have a two-phase heterogeneous construction consisting of a dispersion of separate drug and polymer phases. The different refractive indices of the two phases result in turbidity of the polymer matrix and confer an opaque appearance on the matrix particles.

30

Both microencapsulation of drug materials and matrix formation offer a number of advantages over standard drug delivery systems. These include:

-2-

- (a) modification of the physical properties of drugs, for example by providing liquid drugs in solid form, and the preparation of free-flowing powders;
- 5 (b) the taste masking of bitter drugs and means for concealing unpleasant odours;
- (c) the provision of means for the controlled and sustained release of drugs.

10

GB 2 166 651 A (Elan Corporation) relates to a controlled release drug powder containing discrete microparticles (termed pharماسomes) for use in sustained release compositions and made by solvent evaporation processes. The  
15 microparticles contain an active ingredient, at least one non-toxic polymer and an optional excipient uniformly distributed throughout the microparticle matrix. Pharماسomes prepared from a wide range of drugs and polymer or copolymer materials are disclosed. The working examples  
20 describe microparticles prepared from polymer and copolymer materials including inter alia cellulose acetate butyrate, ethyl cellulose and Eudragit RS-100. Eudragit RS-100 is a copolymer of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups with chloride ion  
25 counter-ions. (Eudragit is a trade name of Rohm Pharma).

European Patent Application, Publication Number 0 212 641 (Searle) relates to a porous drug-polymer matrix, prepared by a solvent evaporation process, and comprising an active  
30 ingredient having basic properties and a pharmaceutically acceptable copolymer having a plurality of carboxylic acid and ester groups (an anionic copolymer) which matrix releases the active ingredient in a medium having a pH value less than 4. The porous drug-polymer matrices of the  
35 invention are described as having utility in masking the

-3-

taste of the active ingredient and effecting its release in the acid environment of the stomach. Porous matrices as described in EPA-0 212 641 are distinguished from microcapsules prepared by complete coating of an active ingredient with a film of anionic polymer material in that microcapsules give rise to significant release of active ingredient only at alkaline pH, the polymeric film being insoluble at acid pH values. The porous nature of the drug-polymer matrix is described as enhancing the release of active ingredient in acidic media. Taste-masking compositions prepared from anionic polymers and copolymers including Eudragit L-100 and Eudragit S-100 are described. Eudragit L-100 and S-100 are copolymers of methacrylic acid and methyl methacrylate.

Japanese Kokai Publication, JP 63174925 (Hisamitsu Pharmaceutical Co.) relates to pharmaceutical microcapsules prepared by a solvent evaporation process and comprising an active drug material and an acrylic macromolecular copolymer. Microparticles are prepared from a range of copolymer materials with active ingredients having acidic properties and are described as having either sustained release properties or a dissolution profile dependent on pH.

It has now been found that by blending polymer materials having differing chemical properties, drug polymer microparticle matrices can be prepared offering both taste-masking and a sustained and controlled drug release profile of practical benefit.

It has also been found that drug release from drug-polymer microparticle matrices is dependent not only on the properties of the polymer material and the drug but also on the physical properties of the matrix, which are in turn dependent on the solvent evaporation conditions under which the matrix is prepared. For example, a homogeneous microparticle matrix prepared from drug materials having

-4-

basic properties and anionic polymer materials, such as Eudragit L-100 or S-100, has been found to release drug under both acid and alkaline conditions, the release being more rapid at alkaline pH than at acid pH. It has also been  
5 shown that release of drug from homogeneous microparticles prepared from drug materials having basic properties and neutral polymeric materials such as Eudragit RS-100, is dependent on the pH of the dissolution medium, in this instance the release rate being more rapid at acid pH  
10 values.

Furthermore, it has surprisingly now been found that a drug-polymer matrix can be prepared conferring both taste-masking and sustained release properties but wherein  
15 the drug release profile is independent of the pH of the dissolution medium. Drug-polymer matrices of this type have particular utility in sustained release compositions for oral administration.

20 Accordingly, the present invention provides a sustained release drug-polymer microparticle matrix comprising an active drug having basic properties, a pharmaceutically acceptable anionic polymer or copolymer, and a pharmaceutically acceptable neutral polymer or copolymer.  
25 In a preferred aspect, the invention provides a drug-polymer matrix, as defined, which is homogeneous. More preferably, the invention provides a drug-polymer matrix, as defined, which is homogeneous and confers a drug release profile that is substantially independent of the pH of the dissolution  
30 medium.

Drug release which is independent of the pH of the dissolution medium is particularly advantageous for orally administrable compositions. It will be appreciated that  
35 when administered by this route, the in vivo rate of drug release will be independent of the pH variation encountered on passage through the gastro-intestinal tract. This ranges from alkalinity in the mouth conferred by the saliva,

-5-

through the acid environment of the stomach, to the alkaline conditions of the intestine. Furthermore, it has surprisingly been found that drug-polymer microparticle matrices of the invention conferring pH-independent drug release have enhanced sustained-release properties.

A drug-polymer matrix of the invention has a dissolution profile wherein the rate of drug release is directly proportional to the square root of time. This is characteristic of a matrix containing dispersed or dissolved drug and indicative of a diffusion-controlled mechanism for drug-release.

Drug-polymer matrices of the invention are prepared by a solvent evaporation process which confers a microparticle construction. Preferably the microparticles are homogeneous and have a compact, substantially spherical and non-porous structure which enhances the sustained release properties of the matrix.

The size of the microparticles of the invention is preferably below 150 $\mu$ m, more suitably below 60 $\mu$ m and preferably below 20 $\mu$ m. A small particle size has the advantage in formulations for oral administration, more especially in liquid formulations, of a non-gritty texture conferring an acceptable mouth-feel. Particle size is suitably determined by sieve analysis.

Active drug materials having basic properties for use in drug-polymer matrices of the invention include drugs having basic functional groups, for example amino groups, which are capable of ionic interaction with polymer material. An ionic interaction contributes to the taste masking and sustained release properties of the matrix and is of particular utility in liquid formulations. A wide range of active drug materials may be used. Representative of active

-6-

drug materials for incorporation into matrices of the invention are drugs such as dextromethorphan, chlorpheniramine, phenylpropanolamine, and also pseudoephedrine, and pharmaceutically acceptable salts thereof. A preferred active drug is the cough suppressant, dextromethorphan.

Pharmaceutically acceptable polymer materials for use in drug-polymer matrices of the invention comprise a neutral component and an anionic component. Either component may itself comprise a polymer or copolymer material. As used herein, the term neutral polymer or copolymer denotes a polymer or copolymer which has no functional groups capable of ionic interaction with a basic drug. A preferred neutral component is the copolymer synthesised from acrylic and methacrylic acid esters which is sold under the trade name Eudragit RS-100. Other suitable neutral components include cellulose derivatives such as ethyl cellulose .

As used herein, the term anionic polymer or copolymer denotes a polymer or copolymer which has acidic properties which render it capable of interaction with a basic drug, for example a polymer or copolymer which has appended thereto acidic functional groups capable of ionic interaction with a basic drug material. Suitable anionic components include acrylic acid and methacrylic acid polymers and copolymers thereof, and copolymers based on combinations of acrylic acid and/or methacrylic acid with acrylic acid esters and/or methacrylic acid esters such as methyl acrylate and methyl methacrylate. Preferred anionic components are copolymers based on combinations of methacrylic acid and methyl methacrylate sold under the trade names Eudragit L and Eudragit S. Other suitable anionic components include cellulose acetate phthalate and cellulose acetate butyrate.



-7-

The combination of neutral and anionic polymer components is a key feature for pH-independent drug release microparticle matrices of the invention. The neutral component also contributes to the compactness and mechanical strength of the matrix. As referred to above, the anionic component contributes, through interaction with the basic drug, to the sustained release properties of the matrix and additionally confers stability to liquid formulations.

10 The ratio of neutral component to anionic component may be varied to suit the desired sustained release properties of the matrix. The chosen ratio will of course be dependent on the acidic properties of the anionic component, for example on the number of acidic functional groups in the polymer or  
15 copolymer of the anionic component which are available for ionic interaction. It will be appreciated that a predominance of one component may upset the balance which maintains pH-independent drug release. Suitably, where the drug is dextromethorphan and the pharmaceutically acceptable  
20 polymer materials are Eudragit copolymers, the neutral and anionic components are present in a weight ratio of 1:1.

The ratio of active drug to pharmaceutically acceptable polymer materials is similarly dependent on the desired  
25 sustained release profile of the active drug ingredient. Drug release is dependent on both the physical and chemical properties of the matrix. The sustained release of drug will be enhanced by optimising the extent of the interaction between the drug and the anionic component of the  
30 pharmaceutically acceptable polymer materials. Excess drug which is not bound to the anionic component will be released from the matrix more rapidly than drug material which is subject to binding, in particular ionic binding. Drug release will also be influenced by the level of compactness  
35 of the microparticles making up the matrix.

-8-

The binding capacity of a polymer or copolymer may be readily ascertained by one of ordinary skill in the art by routine experimentation. For example the equilibrium adsorption isotherm technique may be used to determine drug loading so as to optimise both the drug release profile and taste masking effects.

The invention also provides for the preparation of a drug-polymer microparticle matrix of the invention by a solvent evaporation process.

Matrices of the invention are prepared by a solvent evaporation process which comprises:

- (i) forming a solution of the pharmaceutically acceptable polymer materials in a solvent;
- (ii) dissolving or dispersing the active drug in the polymer solution to achieve a uniform mixture; and
- (iii) removing the solvent from the mixture so formed to provide microparticles having a substantially spherical, matrix construction, by use of an external liquid phase.

A solvent evaporation process of the invention preferably provides a drug-polymer microparticle matrix having a homogeneous construction and more preferably a compact, non-porous construction.

Suitable solvents for solubilising the pharmaceutically acceptable polymer materials include organic solvents such as ketones, alcohols, hydrocarbon solvents, and mixtures of any two or more thereof. Preferred solvents, particularly suitable for use with copolymers sold under the trade name Eudragit, include acetone, ethanol, ethyl acetate,

chloroform, dichloromethane, methanol and isopropanol. Preferably, the active drug is soluble in the polymer solution so formed. Generally, the basic drug is added directly to the polymer solution. Alternatively, it may be convenient to dissolve the drug in an organic solvent prior to mixing with the polymer solution. A uniform mixture of the active drug in the polymer solution may be achieved by thorough mixing.

- 10 Removal of the solvent to give microparticles having the desired physical characteristics is achieved by adding the drug/polymer/solvent mixture to an external liquid phase with which it is immiscible or partially immiscible in the presence of a dispersing agent; emulsifying the two-phase  
15 mixture thus obtained; evaporating the solvent; and isolating the microparticles, suitably by filtration or centrifugation.

Suitable liquids for the external liquid phase include inter  
20 alia aqueous solutions, organic solvents, mineral oils and vegetable oils. The liquid chosen for the external liquid phase will be determined according to the selected drug, the pharmaceutically acceptable polymer material and the organic solvent in which it is dissolved.

- 25  
Suitable dispersing agents include substances such as stearic acid derivatives, for example magnesium stearate and aluminium stearate. A dispersing agent is utilised in order to optimise the microparticle structure. Its concentration  
30 may be varied to influence particle size and to confer a compact, and preferably a substantially non-porous structure.

Efficient emulsification of the external liquid phase with  
35 the drug/polymer/solvent phase is suitably obtained using a high shear mixer. It has been found that efficient emulsification is a primary requirement for a microparticle

-10-

matrix having an average particle size below 150  $\mu\text{m}$ .

Solvent evaporation may be effected at room temperature for volatile solvents or by heating. It is desirable to  
5 maintain efficient mixing throughout the evaporation procedure.

Isolation of the microparticle matrix is suitably followed by repeated washing with a suitable solvent to remove traces  
10 of the external liquid phase, followed by drying.

The properties of the microparticles of the drug-polymer matrix formed by the process hereinbefore described are influenced by a number of factors.

15

For example, factors influencing particle size include the rate of emulsification, the amount of dispersing agent, the viscosity and relative quantities of the  
drug/polymer/solvent and external liquid phases, the  
20 configuration of the mixing vessel and stirrer, and the processing temperature.

Factors influencing the configuration and density of the microparticles include the choice of solvent and its rate of  
25 evaporation, the molecular weight and crystallinity of the polymer materials and the concentration of dispersing agent.

The invention also provides a pharmaceutical composition comprising a drug-polymer microparticle matrix as  
30 hereinbefore defined and a pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers may include conventional additives and excipients such as preservatives,

-11-

binding agents, fillers, tableting agents, lubricants, disintegrants, suspending agents, buffering agents, flavouring agents and colouring agents.

5 A pharmaceutical composition of the invention is preferably formulated for oral administration. Compositions may be in the form of tablets including effervescent and chewable tablets, capsules, lozenges, powders and granules. The matrices of the invention are particularly suitable for use  
10 in liquid formulation compositions, more especially in liquid formulation compositions for oral administration.

Oral liquid preparations may be in the form of syrups or elixirs or may be presented as a dry product for  
15 reconstitution with water or other suitable liquid vehicle before use.

The amount of drug-polymer matrix in a pharmaceutical composition of the invention will be dependent on the chosen  
20 active drug and the dosage level required. The quantity of drug-polymer matrix in a composition may be adjusted to deliver an effective dose of a selected drug to a patient in need of treatment. Pharmaceutical compositions may be in unit dose presentation form.

25

In a further aspect, the invention provides a drug-polymer microparticle matrix, as hereinbefore defined, for use as an active therapeutic substance.

30 The invention is illustrated but not limited by the following examples in which drug-polymer microparticle matrices are prepared incorporating the cough suppressant dextromethorphan.

-12-

The following Examples 1 and 2 and accompanying Figure 1 relate to drug-polymer microparticle matrices of the invention conferring pH-independent drug release. The following Examples 3 and 4 and accompanying Figures 2 and 3 relate to drug-polymer microparticle matrices conferring pH-dependent drug release falling outside the scope of the invention and which are included for comparative purposes.

Drug dissolution was measured according to the basket method of US Pharmacopoeia at 37°C and 100rpm.

#### Example 1

Preparation of drug-polymer matrix microparticles containing dextromethorphan, Eudragit S-100 and Eudragit RS-100

##### Disperse Phase:

Eudragit S-100: 3.75g  
Eudragit RS-100: 3.75g  
20 Propan-2-ol/Acetone: 100ml (50/50 v/v)  
Dextromethorphan hydrobromide: 2.5g

##### Continuous Phase:

Heavy mineral oil: 400ml  
25 Magnesium stearate: 12g

Polymer materials were added to the mixed solvent in a stoppered conical flask and dissolved over a magnetic stirrer for 60 minutes. Drug was added to the polymer solution and dissolved over a magnetic stirrer for 45 minutes. This constituted the disperse phase. Mineral oil was added to a 800ml narrow beaker. Magnesium stearate was added to mineral oil and dissolved over a magnetic stirrer for 60 minutes. This formed the

-13-

continuous phase. The disperse phase was added to the continuous phase. The mixture was emulsified with a high shear mixer for 15 seconds. The emulsion was transferred to a 700ml reaction vessel equipped with a glass anchor stirrer, in a water bath. Solvent evaporation was effected by gradual heating, first up to 35°C for 3 hours followed by 60°C for 3 hours. Microparticles were separated from the continuous phase by centrifugation and then washed several times with n-hexane to remove mineral oil completely. Finally, the matrix microparticles were dried at 45°C for 6 hours. Analysis of the matrix microparticles indicated a drug-loading of 16.2% by weight.

Microparticles were graded into different size ranges by sieving (using British Standard test sieves) and examined by scanning electron microscopy. Both test sieving and SEM indicated a particle size range of 0-150µm with 0-50µm being the major size fraction.

The accompanying Figure 1 is a graphical representation of drug release from dextromethorphan/Eudragit S-100/RS-100 matrix particles made according to the above-described procedure. The graph illustrates that drug release is independent of the pH of the dissolution medium and that a substantially uniform release of drug is sustained over a 12 hour period.

Example 2Preparation of a liquid formulation composition containing dextromethorphan/Eudragit S-100/RS-100 matrix microparticles

5

A liquid formulation was prepared by suspending microparticles obtained from example 1 in a liquid vehicle (247mg/10ml of vehicle). The vehicle composition was as follows:

10

	<u>Excipient</u>	<u>% by weight</u>
	Sorbitol solution	57.2
	1,2-Propylene glycol	2.5
15	Sodium citrate	0.2
	Citric acid	0.2
	Keltrol	0.7
	Sorbic acid	0.1
	Sodium benzoate	0.1
20	Distilled water	39

A particle size fraction of 0-50 $\mu$ m was used.

The weight of microparticles required for the manufacture of the suspension was such as to yield a 40mg/10ml dosage of the drug when in suspension.

Panel tests revealed the microparticle suspension to possess good mouth-feel and to be free from the characteristic bitter taste of dextromethorphan hydrobromide. The formulation was assessed at 18 weeks post-manufacture and found to retain its taste-masking and sustained drug release potential.



-15-

Example 3Preparation of dextromethorphan/Eudragit S-100 matrix  
microparticles

5

The general procedure of Example 1 was repeated using Eudragit S-100 as the only polymer material.

The composition of the disperse and the continuous phases was as follows.

10

## Disperse Phase:

Eudragit S-100: 7.5g

Propan-2-ol/Acetone: 100ml (50/50 v/v)

Dextromethorphan hydrobromide: 2.5g

15

## Continuous Phase:

Heavy mineral oil: 400ml

Magnesium stearate: 12g

20 Scanning electron microscopy and test sieving revealed a particle size range of 0-150 $\mu$ m with 0-50 $\mu$ m being the major size fraction.

The accompanying Figure 2 is a graphical representation of  
25 drug release from microparticles of Example 3. The graph illustrates that release of drug from anionic copolymer microparticles is dependent on the pH of the dissolution medium and that drug release is more rapid and more complete at alkaline pH.

30

-16-

Example 4Preparation of dextromethorphan/Eudragit RS-100 matrix  
microparticles

5

The general procedure of Example 1 was repeated using Eudragit RS-100 as the only polymer material. The composition of the disperse and the continuous phases was as follows.

10

## Disperse Phase:

Eudragit RS-100: 30g

Methanol: 70ml

Dextromethorphan hydrobromide: 4.5g

15

## Continuous Phase:

Heavy mineral oil: 300ml

Magnesium stearate: 4.0g

20 Scanning electron microscopy and test sieving revealed a particle size range of 0-400 $\mu$ m with 180-355 $\mu$ m being the major fraction.

The accompanying Figure 3 is a graphical representation of 25 drug release from microparticles of Example 4. The graph illustrates that release of drug from the neutral copolymer microparticles is dependent on the pH of the dissolution medium and that drug release is more rapid and more complete at acid pH.

30

- 17 -

Claims

1. A sustained release drug-polymer microparticle matrix  
5 comprising an active drug having basic properties, a pharmaceutically acceptable anionic polymer or copolymer, and a pharmaceutically acceptable neutral polymer or copolymer.
- 10 2. A sustained release drug-polymer microparticle matrix as claimed in claim 1 wherein the microparticles have a homogeneous construction.
3. A sustained release drug-polymer microparticle matrix  
15 as claimed in claim 1 or 2 wherein the microparticles have a compact, substantially spherical and non-porous construction.
4. A sustained release drug-polymer microparticle matrix  
20 as claimed in claim 1, 2 or 3 wherein the size of the microparticles is below 150  $\mu\text{m}$ .
5. A sustained release drug-polymer microparticle matrix  
25 as claimed in claim 4 wherein the size of the microparticles is below 60  $\mu\text{m}$ .
6. A sustained release drug-polymer microparticle matrix  
as claimed in any one of claims 1 to 5 wherein drug  
30 release is substantially independent of the pH of the dissolution medium.
7. A sustained release drug-polymer microparticle matrix  
as claimed in any one of claims 1 to 6 wherein the  
35 active drug is dextromethorphan, chlorpheniramine, phenylpropanolamine or pseudoephedrine, or pharmaceutically acceptable salts thereof.

8. A sustained release drug-polymer microparticle matrix  
as claimed in any one of claims 1 to 7 wherein the  
neutral polymer or copolymer comprises ethyl cellulose  
or esters of acrylic and methacrylic acids.
9. A sustained release drug-polymer microparticle matrix  
as claimed in claim 8 wherein the neutral polymer or  
copolymer is a copolymer of acrylic and methacrylic  
acid esters.
10. A sustained release drug-polymer microparticle matrix  
as claimed in any one of claims 1 to 9 wherein the  
anionic polymer or copolymer comprises acrylic and  
methacrylic acid polymers or copolymers thereof,  
copolymers of acrylic and/or methacrylic acid with  
esters of acrylic and/or methacrylic acids, cellulose  
acetate phthalate or cellulose acetate butyrate.
11. A sustained release drug-polymer microparticle matrix  
as claimed in claim 10 wherein the anionic polymer or  
copolymer is a copolymer of methacrylic acid and  
methyl methacrylate.
12. A sustained release drug-polymer microparticle matrix  
comprising dextromethorphan or a pharmaceutically  
acceptable salt thereof, a copolymer of acrylic and  
methacrylic acid esters, and a copolymer of  
methacrylic acid and methyl methacrylate.
13. A sustained release drug-polymer microparticle matrix  
substantially as hereinbefore described with reference  
to Example 1.

14. A solvent evaporation process for preparing a sustained release drug-polymer microparticle matrix as defined in any one of claims 1 to 13 comprising.
- 5 (i) forming a solution of the pharmaceutically acceptable polymer materials in a solvent;
- (ii) dissolving or dispersing the active drug in the polymer solution to achieve a uniform mixture;
- 10 and
- (iii) removing the solvent from the mixture so formed to provide microparticles having a substantially spherical, matrix construction,
- 15 by use of an external liquid phase.
15. A process as claimed in claim 14 wherein the external liquid phase includes a dispersing agent.
- 20 16. A process as claimed in claim 14 or 15 wherein the solvent for the pharmaceutically acceptable polymer materials comprises an organic ketone, alcohol or hydrocarbon solvent, or mixtures thereof.
- 25 17. A process as claimed in claim 16 wherein the solvent comprises acetone, ethanol, ethyl acetate, chloroform, dichloromethane, methanol or isopropanol, or mixtures thereof.
- 30 18. A process as claimed in any one of claims 14 to 17 wherein the external liquid phase comprises an organic solvent, or a mineral or vegetable oil.

19. A process as claimed in any one of claims 15 to 18 wherein the dispersing agent is a stearic acid derivative.
- 5 20. A process for preparing a sustained release drug-polymer microparticle matrix as defined in any one of claims 1 to 13 substantially as hereinbefore described with reference to Example 1.
- 10 21. A pharmaceutical composition comprising a drug-polymer microparticle matrix as defined in any one of Claims 1 to 13 and a pharmaceutically acceptable carrier.
- 15 22. A pharmaceutical composition substantially as hereinbefore described with reference to Example 2.
- 20 23. A pharmaceutical composition for oral administration as a liquid, comprising a suspension of a drug-polymer microparticle matrix as defined in any one of claims 1 to 13 in a pharmaceutically acceptable liquid carrier.
- 25 24. A process for preparing a pharmaceutical composition as defined in claim 21, 22 or 23 comprising admixing a drug-polymer microparticle matrix as defined in any one of claims 1 to 13 with a pharmaceutically acceptable carrier.
- 30 25. A process for preparing a pharmaceutical composition substantially as hereinbefore described with reference to Example 2.
- 35 26. A drug-polymer microparticle matrix as defined in any one of claims 1 to 13 for use as an active therapeutic substance.

1/3




Fig.1

2/3




Fig.2

SUBSTITUTE SHEET



3/3




Fig.3

SUBSTITUTE SHEET

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 91/01140

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.C1.5	A 61 K	9/16
II. FIELDS SEARCHED		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.C1.5	A 61 K	
Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup>		
III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	GB,A,2166651 (ELAN CORPORATION PLC) 14 May 1986, see page 1, lines 22-28, 43-65; page 2, line 60 - page 3, line 9; page 9, example 10; pages 12,13; examples 13,14; claims 1,2,5,15 (cited in the application) ---	1-26
Y	Chemical Abstracts, volume 102, no. 22, 3 June 1985, (Columbus, Ohio, US) Y. Pongpaibul et al.: "Preparation and evaluation of controlled release indomethacin microspheres", see pages 385-386, abstract 191008r, & Drug Dev. Ind. Pharm. 1984, 10(10), 1597-1616 ---	1-26
A	EP,A,0349453 (SOCIETE CORTIAL S.A.) 3 January 1990, see page 2, column 1, lines 3-7; page 2, column 2, lines 19-34; page 3, columns 3-4; example 1; claim 1 --- -/-	1
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
23-10-1991		04.12.91
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		Natalie Weinberg

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0014514 (ORION-YHTYMÄ OY) 20 August 1980, see page 1, lines 2-6; page 4, line 18 - page 5, line 4; page 6, lines 4-10; page 13, lines 20-23 ----	1
A	EP,A,0040590 (AB HASSLE) 25 November 1981, see page 3, lines 11-20; page 3, line 33 - page 4, line 2; page 7, examples 1,2; claims -----	1

# ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9101140

SA 49449

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 20/11/91. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A- 2166651	14-05-86	AU-B- 579415	24-11-88
		AU-A- 4916185	08-05-86
		BE-A- 903540	17-02-86
		BE-A- 903541	17-02-86
		CA-A- 1268051	24-04-90
		CH-A- 669728	14-04-89
		DE-A- 3538429	30-04-86
		FR-A- 2572282	02-05-86
		JP-A- 61109711	28-05-86
		NL-A- 8502951	16-05-86
		SE-A- 8505099	01-05-86
		US-A- 4952402	28-08-90
		US-A- 4940588	10-07-90
EP-A- 0349453	03-01-90	FR-A- 2634377	26-01-90
EP-A- 0014514	20-08-80	CA-A- 1144071	05-04-83
		JP-A- 55129222	06-10-80
		US-A- 4351825	28-09-82
EP-A- 0040590	25-11-81	SE-A- 8003805	22-11-81